Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), bought 5,000 shares at $43.63 ($218K) on 2019-09-11, disclosed to the SEC on 2019-09-11.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |